DK1498129T3 - Anvendelse af adenovirusser, muteret i VA generne, til cancerbehandling - Google Patents

Anvendelse af adenovirusser, muteret i VA generne, til cancerbehandling

Info

Publication number
DK1498129T3
DK1498129T3 DK03744873T DK03744873T DK1498129T3 DK 1498129 T3 DK1498129 T3 DK 1498129T3 DK 03744873 T DK03744873 T DK 03744873T DK 03744873 T DK03744873 T DK 03744873T DK 1498129 T3 DK1498129 T3 DK 1498129T3
Authority
DK
Denmark
Prior art keywords
cancer treatment
adenoviruses
mutated
genes
adenovirus
Prior art date
Application number
DK03744873T
Other languages
English (en)
Inventor
Bonastre Ramon Alemany
Piqueras Manel Maria Cascallo
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Application granted granted Critical
Publication of DK1498129T3 publication Critical patent/DK1498129T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C12N2710/10364—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK03744873T 2002-03-26 2003-03-25 Anvendelse af adenovirusser, muteret i VA generne, til cancerbehandling DK1498129T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200200716 2002-03-26

Publications (1)

Publication Number Publication Date
DK1498129T3 true DK1498129T3 (da) 2006-04-03

Family

ID=27772025

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03744873T DK1498129T3 (da) 2002-03-26 2003-03-25 Anvendelse af adenovirusser, muteret i VA generne, til cancerbehandling

Country Status (13)

Country Link
US (3) US7344711B2 (da)
EP (2) EP1498129B1 (da)
JP (2) JP2005526099A (da)
AT (1) ATE309812T1 (da)
AU (1) AU2003226835B2 (da)
BR (1) BR0308634A (da)
CA (1) CA2478616C (da)
DE (1) DE60302350T2 (da)
DK (1) DK1498129T3 (da)
ES (1) ES2248764T3 (da)
IL (2) IL163745A0 (da)
MX (1) MXPA04009204A (da)
WO (1) WO2003080083A1 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1498129T3 (da) * 2002-03-26 2006-04-03 Oncolytics Biotech Inc Anvendelse af adenovirusser, muteret i VA generne, til cancerbehandling
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
WO2007099401A2 (en) 2005-08-01 2007-09-07 University Technologies International, Inc. Oncolytic attenuated reoviruses for treatment of proliferative disorders
US20070292396A1 (en) * 2006-03-02 2007-12-20 Juan Fueyo Combination therapy with oncolytic adenovirus
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
ES2355882B1 (es) 2009-03-24 2012-02-13 INSTITUT CATALÀ D`ONCOLOGIA (Titular al 50%) Combinación de adenovirus oncolítico y un bloqueador de canal de calcio y su uso para el tratamiento del cáncer.
WO2012121071A1 (ja) * 2011-03-04 2012-09-13 国立大学法人大阪大学 VA-RNAsが発現しないアデノウイルスベクター
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
PL3198009T3 (pl) 2014-09-24 2022-01-24 Salk Institute For Biological Studies Onkolityczne wirusy nowotworowe i sposoby zastosowania
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
WO2018111767A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
AU2018372631B2 (en) 2017-11-22 2025-06-05 Mesoblast International Sarl Cellular compositions and methods of treatment I
JP7430395B2 (ja) 2018-04-09 2024-02-13 ソーク インスティテュート フォー バイオロジカル スタディーズ 複製特質が増強された腫瘍溶解性アデノウイルス組成物
US20210340279A1 (en) 2018-08-31 2021-11-04 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
CN114423860A (zh) 2019-08-05 2022-04-29 迈索布拉斯特国际有限公司 包含病毒载体的细胞组合物及治疗方法
CN115996735A (zh) 2020-08-10 2023-04-21 迈索布拉斯特国际有限公司 细胞组合物和治疗方法
JP2025536260A (ja) 2022-10-11 2025-11-05 イェール ユニバーシティー 細胞透過性抗体の組成物および使用方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648301B2 (ja) * 1983-12-27 1997-08-27 ジエネテイツクス・インスチチユ−ト・インコ−ポレ−テツド 真核細胞の形質転換のための補助ｄｎａを含むベクター
US5079159A (en) * 1983-12-27 1992-01-07 Genetics Institute, Inc. Method for making tissue plasminogen activator
US5002874A (en) * 1987-09-17 1991-03-26 Genetics Institute, Inc. Genetically engineered eucaryotic host cells capable of expressing modified forms of eIF-2α
US5985846A (en) * 1995-06-07 1999-11-16 Baylor College Of Medicine Gene therapy for muscular dystrophy
US6254862B1 (en) * 1997-03-03 2001-07-03 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US6403370B1 (en) * 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
WO1999057296A1 (en) * 1998-05-01 1999-11-11 Genzyme Corporation Partially deleted adenoviral vectors
CA2720361A1 (en) * 1999-11-12 2001-05-25 Oncolytics Biotech, Inc. Viruses for the treatment of cellular proliferative disorders
US20040132675A1 (en) * 2002-02-08 2004-07-08 Calvin Kuo Method for treating cancer and increasing hematocrit levels
WO2003022311A1 (en) * 2001-09-13 2003-03-20 Genvec, Inc. Adenoviral vector and related system and methods of making and use
DK1498129T3 (da) * 2002-03-26 2006-04-03 Oncolytics Biotech Inc Anvendelse af adenovirusser, muteret i VA generne, til cancerbehandling
AU2003297607A1 (en) * 2002-12-02 2004-06-23 Genvec, Inc Materials and methods for treating ocular-related disorders

Also Published As

Publication number Publication date
EP1498129B1 (en) 2005-11-16
US7344711B2 (en) 2008-03-18
US20060233753A1 (en) 2006-10-19
DE60302350D1 (de) 2005-12-22
JP2010184940A (ja) 2010-08-26
IL163745A (en) 2010-02-17
JP2005526099A (ja) 2005-09-02
ES2248764T3 (es) 2006-03-16
US20080089864A1 (en) 2008-04-17
WO2003080083A1 (es) 2003-10-02
BR0308634A (pt) 2005-02-15
US20110053249A1 (en) 2011-03-03
AU2003226835B2 (en) 2006-11-09
CA2478616C (en) 2012-05-29
ATE309812T1 (de) 2005-12-15
AU2003226835A1 (en) 2003-10-08
EP1498129A1 (en) 2005-01-19
HK1071060A1 (en) 2005-07-08
IL163745A0 (en) 2005-12-18
EP1605053A1 (en) 2005-12-14
US20090202489A2 (en) 2009-08-13
MXPA04009204A (es) 2004-11-26
CA2478616A1 (en) 2003-10-02
DE60302350T2 (de) 2006-08-03

Similar Documents

Publication Publication Date Title
IL163745A0 (en) Use of adenoviruses mutated in the va genes for cancer treatment
WO2004024757A3 (en) Modified pna molecules
DK1476562T3 (da) Overekspression af extremozymgener i pseudomonas og nært beslægtede bakterier
WO2009039390A3 (en) The development of glycobiology-based therapeutics for the treatment of brain tumors
WO2004035803A3 (en) Method and nucleic acids for the treatment of breast cell proliferative disorders
NO20084488L (no) Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
DK1390543T3 (da) Nye polynukleotider og polypeptider af IFNalfa-17-genet
Carapelli et al. The complete mitochondrial genome of the Antarctic springtail Cryptopygus antarcticus (Hexapoda: Collembola)
AU4594401A (en) Human urothelial cell specific uroplakin transcriptional regulatory sequences, vectors comprising uroplakin-specific transcriptional regulatory sequences, and methods of use thereof
CY1116649T1 (el) Τεχνητη dna αλληλουχια με βελτιστοποιημενη λειτουργια οδηγου σε 5' (5-utr) για βελτιωμενη εκφραση ετερολογων πρωτεϊνων σε φυτα
WO2008144599A3 (en) Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms
WO2003014388A3 (en) Method and nucleic acids for the analysis of colon cancer
NO20022149D0 (no) Ikke-viralt genleveringssystem
WO2006099259A3 (en) Novel missense mutations and single nucleotide polymorphisms in the rabphillin-3a-like gene and uses thereof
WO2003091416A3 (en) Constant length signatures for parallel sequencing of polynucleotides
MXPA05005120A (es) Secuencias de adn de la region genomica tcd de photorhabdus luminescens.
WO2004070057A3 (de) Verwendung eines neuen polymorphismus im hsgk1-gen zur diagnose der hypertonie und verwendung der sgk-genfamilie zur diagnose und therapie des long-q/t-syndroms
Kawasaki et al. Detection of aberrant methylation of tumor suppressor genes in plasma from cancer patients
NO20022148D0 (no) Ikke-viralt genleveringssystem
WO2002101048A3 (en) NEW POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-7 GENE
AU2002212232A1 (en) Nucleotide sequences which code for the dps gene
AU2001282084A1 (en) Nucleotide sequences which code for the sigh gene
EP1364025A4 (en) A NEW MAPPING OF GENE BN01 TO CHROMOSOME 16Q24.3
WO2002083733A3 (en) Polynucleotides and polypeptides of the ifnalpha-6 gene
WO2006065971A3 (en) Compositions and methods for polynucleotide amplification and detection